CohBar Inc Aktie News

MENLO PARK, Calif.--(BUSINESS WIRE)--On November 20, 2023, CohBar, Inc. (the “Company”) was notified by the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) of its determination pursuant to Nasdaq Listing Rule 5101 that, based upon the Staff's belief that the Company is a “public shell,” and that the continued listing of the Company's securities is no lo...

MILWAUKEE , May 24, 2023 /PRNewswire/ -- Ademi LLP is investigating CohBar (NASDAQ: CWBR) for possible breaches of fiduciary duty and other violations of law in its transaction with Morphogenesis, Inc.  Click here to learn how to join the action https://www.ademilaw.com/case/cohbar-inc or call Guri Ademi toll-free at 866-264-3995.  There is no cost or obligation to you.

CohBar (NASDAQ: CWBR ) stock is soaring higher on Tuesday after the company announced a planned merger with Morphogenesis . CohBar and Morphogenesis are planning for an all-stock merger that will see the two combine to create a new company named “TuHURA Biosciences, Inc.” This company will continue to trade its shares on The Nasdaq Capital Market.

MENLO PARK, Calif. and TAMPA, Fla. , May 23, 2023 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) (“CohBar” or the “company”) and Morphogenesis, Inc. (“Morphogenesis”), a privately-held Phase 2/3 clinical-stage biotechnology company developing novel personalized cancer vaccines and tumor microenvironment modulators to overcome resistance to current immunotherapies, today announced that they hav...

CohBar, Inc. (NASDAQ:CWBR ) Q3 2022 Results Conference Call November 8, 2022 10:00 AM ET Company Participants Jordyn Tarazi - Director of IR Joseph Sarret - CEO Kent Grindstaff - SVP, Research Jeffrey Biunno - CFO Conference Call Participants Kemp Dolliver - Brookline Capital Markets Operator Good afternoon. My name is Matt, and I will be your conference operator for today.

Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET

A 1-for-30 reverse split of CohBar (CWBR) stock has gone into effect today. These are the details.

MENLO PARK, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, today announced that its Board of Directors (the “Board”) has approved a 1-for-30 reverse stock split o...